Cargando…
A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia
This study of vosaroxin evaluated dose-limiting toxicity (DLT), maximum-tolerated dose (MTD), pharmacokinetics (PK), clinical activity and pharmacodynamics in relapsed/refractory leukemia. Dosing was weekly (days 1, 8 and 15) or twice weekly (days 1, 4, 8 and 11). Seventy-three treated patients had...
Autores principales: | Lancet, JE, Ravandi, F, Ricklis, RM, Cripe, LD, Kantarjian, HM, Giles, FJ, List, AF, Chen, T, Allen, RS, Fox, JA, Michelson, GC, Karp, JE |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576993/ https://www.ncbi.nlm.nih.gov/pubmed/21760592 http://dx.doi.org/10.1038/leu.2011.157 |
Ejemplares similares
-
Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models
por: Gravina, Giovanni Luca, et al.
Publicado: (2017) -
Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia
por: Jamieson, Gene C., et al.
Publicado: (2016) -
Therapies for acute myeloid leukemia: vosaroxin
por: Sayar, Hamid, et al.
Publicado: (2017) -
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia
por: Stuart, Robert K, et al.
Publicado: (2015) -
Radiosensitization by the novel DNA intercalating agent vosaroxin
por: Gordon, Ira K, et al.
Publicado: (2012)